HBV Clinical Trial
Official title:
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for Treating Decompensated Liver Cirrhosis Associated With HBV
The purpose of this study was to observe the safety ,tolerability ,Efficacy dose of human umbilical cord mesenchymal stem cells in patients of decompensated liver cirrhosis with HBV.
Investigators plan to recruit 24 voluntary patients of decompensate liver cirrhosis with HBV, dividing them into 3 group：1) low-dose group: 100mL with 2.5×10^7 cells；2) medium-dose group: 100mL with 5.0×10^7 cells；3) high-dose group: 100mL with 1.0×10^8 cells. Each group contains 8 patients. Investigators treat the participants with human umbilical cord mesenchymal stem cells via venous transfusion. First investigators arrange a whole test for participants, such as vital sign examination, laboratory test, ECG, CT, MRI, ultrasound etc. Investigators screen these patients with a complete eligibility criteria. Then investigators proceed the therapy in the 1st, 8th and 15th day. There are 8 times of follow-up visit for these patients, 4 times of those are proceeded during the hospitalization, while other 4 times happens after the discharge. The follow-up visit includes vital sign examination, laboratory test, ECG, CT, MRI, ultrasound, Child-Pugh grade, MELD grade, SF-36 test. These follow-up visit last 24 weeks since the first treatment. After that, investigators also arrange a survival visit through phone or clinic each 6 months, lasting another 1.5 years. The main object of this research is investigating the survival rate, promotion of the liver function, improvement of health, safety of hUC-MSCs, tolerability of patients, for exploring a new way for the therapy of decompensated liver cirrhosis with HBV. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05951751 -
The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
|
N/A | |
| Completed |
NCT04519710 -
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
|
N/A | |
| Recruiting |
NCT04562051 -
Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
|
||
| Recruiting |
NCT04683341 -
Tenofovir Alafenamide in HBV Related Decompensated Liver
|
Phase 4 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Completed |
NCT02044068 -
Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women
|
N/A | |
| Completed |
NCT03239353 -
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04904835 -
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
|
||
| Terminated |
NCT04059198 -
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
|
Phase 2 | |
| Not yet recruiting |
NCT05293158 -
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
|
N/A | |
| Not yet recruiting |
NCT05028322 -
Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
|
Phase 2 | |
| Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT02312531 -
Prevention for Mother-to-infant Transmission of HBV
|
N/A | |
| Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
| Not yet recruiting |
NCT06307808 -
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
|
||
| Completed |
NCT03149627 -
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
|
||
| Recruiting |
NCT04886336 -
The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
|
||
| Recruiting |
NCT04568265 -
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
|
Phase 2 | |
| Terminated |
NCT02826018 -
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 1 | |
| Completed |
NCT01970254 -
Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
|